Abuse-resistant amphetamine prodrugs

a technology of amphetamine and prodrugs, applied in the field of amphetamine compounds, can solve the problems of temporary exhilaration, amphetamine abuse, amphetamine derivatives, etc., and achieve the effect of minimizing the risk of adverse side effects

Inactive Publication Date: 2010-02-09
TAKEDA PHARMA CO LTD
View PDF114 Cites 43 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]Another embodiment of the invention is directed to a method of reducing patient to patient variability of amphetamine levels among a group of patients. The method entails daily (preferably once daily) oral administration to each patient in the group of a prodrug of amphetamine or a pharmaceutically acceptable salt of the prodrug, wherein the amphetamine is covalently bound to a peptide comprising 1 to 10 amino acids. In one preferred embodiment, a pharmaceutical composition consisting essentially of the prodrug of amphetamine or a pharmaceutically acceptable salt thereof is administered. A preferred prodrug is L-lysine-d-amphetamine and pharmaceutically acceptable salts thereof, such as L-lysine-d-amphetamine dimesylate.
[0020]Yet another embodiment is a method of treating ADHD in a patient in need thereof while minimizing the risk of adverse side effects due to the mode of treatment, comprising:

Problems solved by technology

Because of their stimulating effects, amphetamines, including amphetamine derivatives and analogs, are subject to abuse.
Legitimate amphetamine users that develop drug tolerances are especially susceptible to becoming accidental addicts as they increase dosing in order to counteract their increased tolerance of the prescribed drugs.
Additionally, it is possible for individuals to inappropriately self-administer higher than prescribed quantities of the drug or to alter either the product or the route of administration (e.g., inhalation (snorting), injection, and smoking), potentially resulting in immediate release of the active drug in quantities larger than prescribed.
When taken at higher than prescribed doses, amphetamines can cause temporary feelings of exhilaration and increased energy and mental alertness.
Extended release formulations of amphetamines, e.g., Adderall XR®, have an increased abuse liability relative to the single dose tablets because each tablet of the sustained release formulation contains a higher concentration of amphetamine.
Sustained release formulations may also provide uneven release.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Abuse-resistant amphetamine prodrugs
  • Abuse-resistant amphetamine prodrugs
  • Abuse-resistant amphetamine prodrugs

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Synthesis of Peptide Amphetamine Conjugates

[0253]Peptide conjugates were synthesized by the general method described in FIG. 1. An iterative approach can be used to identify favorable conjugates by synthesizing and testing single amino acid conjugates, and then extending the peptide one amino acid at a time to yield dipeptide and tripeptide conjugates, etc. The parent single amino acid prodrug candidate may exhibit more or less desirable characteristics than its di- or tripeptide offspring candidates. The iterative approach can quickly suggest whether peptide length influences bioavailability.

General Synthesis of Single Amino Acid Amphetamine Conjugates

[0254]To a solution of a protected amino acid succinimidyl ester (2.0 eq) in 1,4-dioxane (30 mL) was added d-amphetamine sulfate (1.0 eq) and NMM (4.0 eq). The resulting mixture was allowed to stir for 20 h at 20° C. Water (10 mL) was added, and the solution was stirred for 10 minutes prior to removing solvents under reduced p...

example 2

Synthesis of L-lysine-d-amphetamine

[0258]L-lysine-d-amphetamine was synthesized by the following methods.

[0259]a. Preparation of HCl Salt (see FIG. 3)

[0260]i. Coupling

[0261]

MolarReagentsMWWeightmmolesEquivalentsd-amphetamine free base135.24.75g35.131Boc-Lys(Boc)-OSu443.515.58g35.131Di-iPr-Et-Amine129906mg7.030.2, d = 0.74,1.22 mL1,4-Dioxane—100mL——

[0262]To a solution of Boc-Lys(Boc)-OSu (15.58 g, 35.13 mmol) in dioxane (100 mL) under an inert atmosphere was added d-amphetamine free base (4.75 g, 35.13 mmol) and DIPEA (0.9 g, 1.22 mL, 7.03 mmol). The resulting mixture was allowed to stir at room temperature overnight. Solvent and excess base were then removed using reduced pressure evaporation. The crude product was dissolved in ethyl acetate and loaded on to a flash column (7 cm wide, filled to 24 cm with silica) and eluted with ethyl acetate. The product was isolated, the solvent reduced by rotary evaporation, and the purified protected amide was dried by high-vac to obtain a white...

example 3

Synthesis of Ser-Amp

[0275]Ser-Amp was synthesized by a similar method (see FIG. 4) except the amino acid starting material was Boc-Ser(O-tBu)-OSu and the deprotection was done using a solution of trifluoroacetic acid instead of HCl.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
particle sizeaaaaaaaaaa
d90 particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Description

CROSS REFERENCE RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. application Ser. No. 11 / 400,304, filed Apr. 10, 2006, which in turn, (a) claims benefit under 35 U.S.C. 119(e) to U.S. Provisional Application Nos. 60 / 669,385 filed Apr. 8, 2005, 60 / 669,386 filed Apr. 8, 2005, 60 / 681,170 filed May 16, 2005, 60 / 756,548 filed Jan. 6, 2006, and 60 / 759,958 filed Jan. 19, 2006; (b) is a continuation-in-part of U.S. application Ser. No. 10 / 857,619 filed Jun. 1, 2004, which claims the benefit of under 35 U.S.C. 119(e) to U.S. Provisional Application Nos. 60 / 473,929 filed May 29, 2003 and 60 / 567,801 filed May 5, 2004; and (c) is a continuation-in-part of U.S. application Ser. No. 10 / 858,526 filed Jun. 1, 2004, which, in turn, is a continuation-in-part of international application PCT / US03 / 05525 filed Feb. 24, 2003, which claims priority to U.S. Provisional Application Nos. 60 / 358,368 filed Feb. 22, 2002 and 60 / 362,082 filed Mar. 7, 2002; application Ser. No. 10 / 858,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K38/00A61K31/785A61K51/00G01N33/00G01N33/53
CPCA61K31/165A61K31/27C07C237/06A61K47/48038Y10T436/173845Y10S436/901A61K47/542
Inventor MICKLE, TRAVISKRISHNAN, SUMABISHOP, BARNEYLAUDERBACK, CHRISTOPHERMONCRIEF, JAMES SCOTTOBERLENDER, ROBERTPICCARIELLO, THOMASPAUL, BERNHARD J.VERBICKY, CHRISTOPHER A.
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap